Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06424132 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Thermogenic Silencer Regulatory Factors in Humans

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment increased: 8 → 80 participants
    • Trial arms changed: 3 → 2
    v4
  2. Enrollment target: estimated 120 to confirmed 8v3 Show 4 more changesShow less
    • Primary completion date: May 2026 to Dec 4, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: May 2027 to Dec 4, 2026
    • Site details revised
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 2024 to Aug 16, 2024
    • Secondary endpoints: details revised at 1 of 4 entries
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A promising approach to correct the metabolic dysfunction associated with obesity is to activate brown fat non-shivering thermogenesis (NST). A critical limitation with NST as a therapeutic option, however, is that this beneficial process is silenced under human physiological temperature conditions and the mechanisms of how this occurs is unknown. This study will be the first to identify human NST silencing factors that may be targeted for the treatment of obesity and metabolic disorders.
Trial Details
NCT Number NCT06424132
Lead Sponsor Rockefeller University
Collaborators: Cornell University
Conditions
(from sponsor)		 Obesity, Metabolic Disease, Cold Exposure
Related terms Metabolic Diseases, Obesity
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov